DEBRA News: Research
Amryt Pharma announces positive top line results from pivotal phase 3 “EASE” trial of wound healing gel in Epidermolysis Bullosa
11 September 2020
We are excited to share the positive results of a global trial by Amyrt Pharma of a topical therapeutic gel treatment which could potentially increase the speed of wound healing for people affected by Epidermolysis Bullosa (EB).
Spray-on Gene Therapy with RenovaCare SkinGun™ in New Study Underway at King’s College London
7 April 2020
RenovaCare Inc. have announced that the Company’s novel SkinGun™ is now being used to apply regenerative cells in a preclinical study of new gene therapies, underway at King’s College London.
Researcher Dr Maria Papanikolaou collaborates with DEBRA UK to visit the Miami Itch Center
29 January 2020
Dr Maria Papanikolaou shares her experience of visiting the Miami Itch Center with the support of DEBRA UK. Dr Papanikolaou is currently working on the PRUMEC trial, which focuses on explaining the cause of itch in an inherited skin condition known as Dystrophic Epidermolysis Bullosa.
DEBRA Funds 4th year towards Novel Gene Technology for Epidermolysis Bullosa
1 October 2019
We are pleased to announce funding for a fourth year of the University of Dundee’s research into novel gene technology for treating Epidermolysis Bullosa has been agreed.
Merger of US Pharmaceutical and Cell & Gene Therapy companies has potential to develop multiple promising new therapies
20 September 2019
The announcement several days ago of a merger of two US companies in the field of dermatology and cell and gene therapy is very positive news for the future development of therapies and products for EB.
Make a difference
Please help us fund vital healthcare such as specialist EB nurses as well as research, care and life-changing support.